Page last updated: 2024-11-05

alpha phellandrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha phellandrene: can be irritating to, & absorbed by the skin; ingestion can cause vomiting, diarrhea; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alpha-phellandrene : One of a pair of phellandrene cyclic monoterpene double-bond isomers in which both double bonds are endocyclic (cf. alpha-phellandrene, where one of them is exocyclic). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7460
CHEMBL ID3188459
CHEBI ID50035
MeSH IDM0046925

Synonyms (72)

Synonym
a-phellandrene
nsc1842 ,
.alpha.-phellandrene
phellandrene,alpha
nsc-1842
alpha-phellandrene
1,3-cyclohexadiene, 2-methyl-5-(1-methylethyl)-, (r)-
1,3-cyclohexadiene, 2-methyl-5-(1-methylethyl)-
menthadiene
einecs 202-792-5
alpha phellandrene
fema no. 2856
hsdb 1130
brn 1280394
alpha-phellandrene (natural)
(-)-2-methyl-5-(1-methylethyl)-1,3-cyclohexadiene
phellandrene, alpha-
alpha-phellandrene, stabilized
alpha-fellandrene
2-methyl-5-isopropyl-1,3-cyclohexadiene
4-isopropyl-1-methyl-1,5-cyclohexadiene
CHEBI:50035 ,
alpha-phellandren
p-mentha-1,5-diene
dihydro-p-cymene
5-isopropyl-2-methylcyclohexa-1,3-diene
2-methyl-5-(propan-2-yl)cyclohexa-1,3-diene
1-isopropyl-4-methyl-2,4-cyclohexadiene
5-isopropyl-2-methyl-1,3-cyclohexadiene
99-83-2
1-methyl-4-isopropyl-1,5-cyclohexadiene
2-methyl-5-(1-methylethyl)-1,3-cyclohexadiene
2-methyl-5-propan-2-ylcyclohexa-1,3-diene
M0051
tox21_302550
NCGC00256667-01
cas-99-83-2
dtxsid4047593 ,
dtxcid2027593
1329-99-3
49jv13xe39 ,
unii-49jv13xe39
3-05-00-00342 (beilstein handbook reference)
FT-0607984
AKOS015913085
.alpha.-phellandrene, (+/-)-
.rho.-mentha-1,5-diene
.alpha.-phellandrene [mi]
alpha-phellandrene [hsdb]
.alpha. phellandrene
(+/-)-.alpha.-phellandrene
.alpha.-phellandrene [fhfi]
alpha-phellandrene [fcc]
5-isopropyl-2-methyl-cyclohexa-1,3-diene
.alpha.-fellandrene
OGLDWXZKYODSOB-UHFFFAOYSA-N
CHEMBL3188459
alpha-phellandrene, natural, >=85%, fg
fema 2856
Q19606345
ferricorthophosphatehydrate
AMY22322
E77746
(+/-)-alpha-phellandrene 100 microg/ml in methanol
mfcd00040419
1,3-cyclohexadiene, 2-methyl-5-(1-methylethyl)-; p-mentha-1,5-diene (8ci); 2-methyl-5-(1-methylethyl)-1,3-cyclohexadiene; 6-isopropyl-3-methyl-1,3-cyclohexadiene; menthadiene; alpha-phellandrene
-phellandrene
AS-75606
(+/-)-alpha-phellandrene
EN300-7644670
SY052143
rho-mentha-1,5-diene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
volatile oil componentAny plant metabolite that is found naturally as a component of a volatile oil.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phellandrene
cyclohexadiene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
trichome monoterpenes biosynthesis210
trichome monoterpenes biosynthesis29

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
farnesoid X nuclear receptorHomo sapiens (human)Potency13.80220.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency30.63790.005428.02631,258.9301AID1346982
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency60.24500.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.89)18.2507
2000's6 (11.32)29.6817
2010's33 (62.26)24.3611
2020's13 (24.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.83 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (98.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]